NewzA Food and Drug Administration advisory panel voted 10 to 0 on Wednesday to endorse Galleri, a multi-cancer early detection blood test developed by the biotechnology firm Grail. The panel concluded that the potential benefits of the screening tool outweigh its associated risks.
The endorsement marks a significant step for the diagnostic test, which is designed to identify multiple types of cancer through a single blood draw. The panel's recommendation will now be considered by the FDA as it determines the regulatory path forward for the product.
In-depth summary · AI, neutral